You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD79A/CD79B

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation Trial in Zhengzhou (Rituximab, Zanubrutinib,

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Zhengzhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jan 22, 2022

Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

Not yet recruiting
  • Non-hodgkin Lymphoma
  • +9 more
  • CD79b-19 CAR T cells
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 6, 2023

Lymphomas, B-cell Lymphomas Trial in Houston (JV-213, Leukapheresis)

Not yet recruiting
  • Lymphomas
  • B-cell Lymphomas
  • Houston, Texas
    The University of Texas M D Anderson Cancer Center
Mar 6, 2023

Non-GCB/ABC DLBCL, With and Without MyD88 and/or CD79B Mutations Trial in Cleveland, Toledo (Mivavotinib)

Recruiting
  • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
  • With and Without MyD88 and/or CD79B Mutations
  • Evanston, Illinois
  • +6 more
Dec 12, 2022

Healthy Subjects Trial in Baltimore (MGD010, Placebo, Hepatitis A vaccine)

Completed
  • Healthy Subjects
  • Baltimore, Maryland
    PAREXEL Baltimore Early Phase Clinical Unit
Feb 4, 2022

B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/79b T cells)

Recruiting
  • B Cell Malignancies
  • bi-4SCAR CD19/79b T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 28, 2022

Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma Trial in China (Zanubrutinib)

Recruiting
  • Relapsed Diffuse Large B-cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • Hefei, Anhui, China
  • +21 more
Mar 2, 2022

Antibody-mediated Rejection, Kidney Tranplant Trial in Hangzhou (Daratumumab)

Not yet recruiting
  • Antibody-mediated Rejection
  • Kidney Tranplant
  • Hangzhou, Zhejiang, China
    79# Qingchun Road
Jun 21, 2023

CD79 Mutant or ABC-subtype DLBCL Trial in Worldwide (AEB071, Everolimus)

Completed
  • CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma
  • Saint Louis, Missouri
  • +14 more
Dec 16, 2020

DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • +2 more
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Sep 5, 2023

DLBCL Trial in Worldwide (AEB071)

Terminated
  • Diffuse Large B-Cell Lymphoma
  • Duarte, California
  • +23 more
Dec 16, 2020

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

Relapsed and/or Refractory Acute Lymphoblastic Leukemia, Relapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma Trial in

Not yet recruiting
  • Relapsed and/or Refractory Acute Lymphoblastic Leukemia
  • Relapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma
  • CD79b CAR-T Cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Oct 23, 2020

Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 10, 2023

B-cell NHL, CLL Trial (CARCIK-CD19)

Not yet recruiting
  • B-cell NHL
  • CLL
  • CARCIK-CD19
  • (no location specified)
May 19, 2023

B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • Cyclophosphamide injection
  • +2 more
  • Charleston, South Carolina
    Hollings Cancer Center at Medical University of South Carolina
Jan 18, 2023

B-Cell Leukemia, B-Cell Lymphoma, B-cell Tumors Trial in Kunming (Anti-CD19 Autologous CAR-T Cell Infusion)

Recruiting
  • B-Cell Leukemia
  • +2 more
  • Anti-CD19 Autologous CAR-T Cell Infusion
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force of People's Libe
Jul 9, 2023

B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)

Not yet recruiting
  • B-cell Non-Hodgkins Lymphoma (B-NHL)
  • (no location specified)
Jan 5, 2023

CNS Lymphoma Trial in Nanchang (Human CD19-CD22 Targeted T Cells Injection)

Recruiting
  • Central Nervous System Lymphoma
  • Human CD19-CD22 Targeted T Cells Injection
  • Nanchang, Jiangxi, China
    The Second Affiliated Hospital of Nanchang University
Dec 13, 2022

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)

Recruiting
  • B-cell Lymphoma
  • +5 more
  • Louisville, Kentucky
    Norton Cancer Institute
Jan 24, 2023

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Trial in Tianjin (CD19-CD22 CAR-T cells)

Active, not recruiting
  • Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
  • CD19-CD22 CAR-T cells
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Aug 2, 2022

B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)

Active, not recruiting
  • B-cell Lymphoma
  • PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University School of Med
Sep 28, 2022

Glioblastoma Multiforme of Brain Trial in Duarte (CHM-1101 CAR-T cells)

Not yet recruiting
  • Glioblastoma Multiforme of Brain
  • CHM-1101 CAR-T cells
  • Duarte, California
    City of Hope Medical Center
Dec 19, 2022

Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Large B-cell Lymphoma Trial in Kaohsiung, Taipei

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • CD19-targeted chimeric antigen receptor T-cell
  • Kaohsiung, Taiwan
  • +2 more
Oct 25, 2022